{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046043","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.005469+00:00","generated_at":"2026-05-30T00:29:20.869213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem Biosciences Q3 2024 operating loss narrows to $2.4M; acquires SOLOSEC, licenses Phexxi in Middle East","bullets":["Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.","Net loss attributable to common stockholders $2.4M ($0.02/sh) vs net income $66.0M ($15.34/sh) in Q3 2023 due to prior-year debt extinguishment gain.","Acquired global rights to SOLOSEC (secnidazole) 2g oral granules, FDA-approved for BV and trichomoniasis, relaunched as single-dose treatment.","Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; UAE regulatory submission on track by year-end 2024.","Aditxt invested $5.0M since May 2024, including $1.3M in Q3 and $2.7M in October 2024, under amended merger agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046043","json":"https://secwatch.observer/filing/0001493152-24-046043.json","markdown":"https://secwatch.observer/filing/0001493152-24-046043.md","text":"https://secwatch.observer/filing/0001493152-24-046043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/0001493152-24-046043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:29:20.869213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}